For more information about the usage of HDAC inhibitors, IDH1/2 inhibitors, SAM cycle inhibitors and other inhibitors or activators of epigenetic modulation in cancer, please see the excellent reviews by Falkenberg et al., Eckschlager et al., Wong et al. and Cheng et al. (Falkenberg and Johnstone, 2014; Eckschlager et al., 2017; Wong et al., 2017; Cheng et al., 2019). This evidence concerns the gene IDH1 and cancer.